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Successful Treatment of Cryptococcal Meningitis 
with Voriconazole in a Kidney Transplant 
Recipient 
S. Tschudin 1, L. Elzi 1, M. Mayr 2, U. Fl0ckiger 1., 
J. Steiger 2. IDivision of Infectious Diseases & 
Hospital Epidemiology, University Hospital Basel, 
Switzerland, 2Department of Transplantation 
Immunology and Nephrology, University Hospital 
Basel, Switzerland 
Background: Current treatment for cryptococ- 
cal (C) meningitis consists in an initial course of 
amphotericin B (AMPHO B) combined with Flucy- 
tosine (5-FC) for two weeks, followed by an oral 
suppressive therapy with Fluconazole (FLU). 
Objectives: We report the case of a kidney- 
transplant recipient successfully treated with 
Voriconazole (VOR) for C meningitis. 
Case: Four years after kidney transplantation a 
42-y-old woman was admitted with a 3 month his- 
tory of headache, and a 3 week history of nuchal 
rigidity, double vision, memory loss and fever. 
Immunosuppression consisted of sirolimus/aza- 
thioprine, changed to sirolimus/prednisone when 
C meningitis was diagnosed. Additionally, re- 
current episodes of hemolytic uremic syndrome 
were treated by plasmapheresis. White blood- 
cell count and CRP were normal, however CD4 
cells were reduced (196 cells/uL). Cerebrospinal 
Fluid (CSF) analysis showed an elevated intracra- 
nial pressure, elevated leukocytes (8/ul), pro- 
tein (1419 mg/l) and lactate (5.2 mmol/l) and a low 
glucose (<0.Smmol/l). India ink preparation and 
CSF culture were positive for C. neo[ormans. C 
antigen was 1:128 in serum and 1:512 in CSE MICs 
for AMPHO B were 0.5 mg/l, for FLU 8 mg/l and for 
VOR 0.064 mg/l. Blood cultures remained negative. 
Antifungal therapy with AMPHO B and 5-FC was 
initiated. Due to a rash, 5-FC was stopped after 
2 days. 10 days tater, CSF cultures remained pos- 
itive but clinical symptoms had resolved. AMPHO 
B was replaced by oral VOR because of the good 
penetration into CSF and the relative high MIC of 
FLU. CSF concentrations of VOR were between 0.75 
and 1.47mg/l. As cultures still were positive after 
5 weeks of therapy, VOR was replaced by liposo- 
male AMPHO B for another two weeks. Under this 
regimen CSF cultures still remained positive and 
serum C antigen rose from 1 : 128 to 1:1024. There- 
fore, therapy was changed back to VOR. Finally, 
ten weeks after antifungal therapy was started, 
cultures became negative and CSF antigen (1:64) 
as well as serum antigen (1:128) decreased. After 
18 months of treatment with VOR CSF and serum 
C antigen became undetectable. 
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Conclusions: We demonstrate successful treat- 
ment of C meningitis with oral VOR in an immuno- 
compromised patient. Of interest, an increase of 
C antigen was noted under monotherapy with li- 
posomale AMPHO B. Our patient showed a rapid 
clinical response to the antifungal treatment, white 
lacking in microbiological response as CSF cultures 
remained positive for ten weeks. 
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Cytomegalovirus (CMV) Specific T Cells in a Liver 
Transplant Recipient with Severe CMV Retinitis 
and Immune Reconstitution Syndrome 
A. Egli 1 *, B. Miillhaupt 2, J.D. Seebach 3, 
N.J. Mueller 4, H.H. Hirsch 1,s. 1Transplantation 
Virology, /Medical/Microbiology, University of 
Basel, Basel, Switzerland, 2Gastroenterology 
and Hepatology, 3Internal/Medicine, 4Division of 
Infectious Disease and Hospital Epidemiology, 
University Hospital Zurich, Zurich, Switzerland, 
51n[ectious Diseases and Hospital Epidemiology, 
University Hospital Basel, Basel, Switzerland 
Background: Since CMV seronegative recipients of 
seropositive organ transplants are at high risk for 
CMV infection and disease they qualify for prophy- 
laxis using oral ganciclovir (GCV) or valGCV. Albeit 
rare, the occurrence of GCV-resistant CMV strains 
under treatment warrants the intravenous appli- 
cation of foscarnet as well as dose reductions of 
the immunosuppressive drugs use to prevent graft 
rejection. Paradoxically, the recovery of immune 
functions may result in a worsening of the clinical 
symptoms referred to as immune reconstitution 
syndrome (IRS). IRS is a well-known phenomenon i
HIV infected patients initiating HAART, but has only 
rarely been described in patients following solid 
organ transplantation. 
Objectives: We report a case of GCV-resistant pri- 
mary CMV infection early after liver transplanta- 
tion with severe bilateral CMV retinitis. 
Methods: CMV-antigenemia, CMV IgG/IgM titers 
and quantitative CMV PCR measurements were car- 
ried out following standard procedures. Peripheral 
blood mononudear cells (PBMC) were stimulated 
with viral protein (CMV lysat, pp72, pp65), and 
SEB as a positive control. CMV specific interferon 
gamma (IFNy) production of CD4+ and CD8+ T cells 
was measured by intracellular staining and flow cy- 
tometry analysis. Localization of the GCV-induced 
viral phosphotransferase (UL97) mutation was de- 
termined by real-time PCR. 
Results: A CMV seronegative recipient of a CMV 
seropositive liver transplant was treated with oral 
valGCV for the first three months posttransplant. 
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One week after withdrawal of vatGCV, she de- 
veloped primary CMV infection with pp65 anti- 
genemia (1200/250,000 [eukocytes). Response to 
intravenous treatment with GCV was slow with 
persisting viral replication. A mutation of the vi- 
ral phosphotransferase (UL97) was detected. CMV 
replication and viremia became undetectabLe af- 
ter reduction of immunosuppression i  combination 
with continuing vaLGCV treatment. The peripheral 
Lymphocyte counts increased, but the patient de- 
veloped visual disturbances. A diagnosis of severe 
biLateraL CMV retinitis was made and a therapy with 
foscarnet and eventuaLLy cidofovir was initiated. 
ALthough CMV retinitis was controLLed, 4 month 
Later vitrectomy became necessary due to retinal 
detachment. CMV replication recurred to Low but 
detectable (5629c/m[). The frequency of IFNy- 
producing CMV specific CD4+ and CD8+ T ceLLs after 
stimulation in vitro with CMV [ysate was 0.365% 
and 0.245%, with CMV pp65 peptide pools 0.19% 
and 0.085%, respectively. RemarkabLy, the IFNy- 
response to CMV pp72 (IE1) was 0.235% in CD4+, 
but 4.675% in CD8+ T ceLLs (Figure 1 ). 
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Conclusion: In this patient, the cLinicaL signs of 
retinitis foLLowed reduced immunosuppression, re- 
covery of Lymphocyte counts and the mounting 
of a highly selective pp72 CD8+ T celt response 
that was unmatched by a corresponding CD4+T- 
celt response. A prominent pp72 specific CD8+ T 
celt response without balancing CD4+ T-ceLts might 
provide an immunoLogicaL correlate CMV-specific 
IRS. In such a situation, the use of steroids needs 
to be evaluated. 
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Oral  Candida Colonization in Solid Organ 
Transplant Recipients 
A. Dongari-Bagtzogtou*, E. Ioannidou, P. Dwivedi, 
J. Burteson, D. HULL. University o[ Connecticut, 
School of Dental Medicine, Farrnington, CT, USA 
Background: Oral Candida colonization has been 
reported to be associated with a greater risk for 
esophagitis and pneumonitis in solid organ trans- 
plant recipients; however a systematic analysis of 
the oral Candida titers and species has not been 
previously conducted in this population. The ob- 
jectives of this study were to determine the preva- 
Lence of oropharyngea[ candidiasis and to define 
the oral carrier status, Candida titers and species 
in this population. 
Methods: 63 kidney and heart transplant subjects 
were recruited from Hartford Hospital using the 
foLLowing criteria: 1. cLinicaLLy stable; 2. at Least 
one year post transplant; 3. no history of antifungaL 
or antibiotic use within the Last 4 months. Con- 
trol subjects (n--30) were age- and sex-matched, 
systemicaLLy healthy individuals. Subjects received 
an oral cLinicaL examination. Swabs from the oral 
mucosa and a standardized amount of unstimu- 
Lated saliva were plated on Chromagar ® plates, 
and CFU/mL were caLcuLated. Initial speciation was 
based on colony color and was confirmed by stan- 
dard germination and biotyping (carbohydrate as- 
similation) assays. 
Results: 1 of 63 transplant and 0 of 30 control 
subjects had oral infection with C. albicans. A sig- 
nificantly higher frequency of asymptomatic coLo- 
nization was noted in transplant recipients (57.1%) 
compared to healthy controls (36.6%). In addition, 
the transplant group had significantly higher Can- 
dida titers than the control group. 83.3% of the 
transplant carriers were colonized by C. albicans, 
16.6% by C. 9labrata and 1% by C. lusitaniae. 
22.2% of transplant carriers were colonized by 
more than one species, with the most frequent 
combination being C. albicans and C. 9labrata. 81% 
of the control carriers were colonized by C. al- 
bicans, 0% by C. 9labrata and 18% by C. lusi- 
taniae. None of the control subjects were coL- 
onized by more than one species. The preva- 
Lence of xerostomia did not differ between test 
and control groups but the prevalence of dia- 
betes was significantly higher in the transplant 
group. 
Conclusions: Increased oral Candida carriage rate 
and titers were found in solid organ transplant 
subjects who are at Least one year post-transpLant. 
ALthough the majority of these subjects are colo- 
